Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
Press release cover image

Sep 24, 2026

Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology

WILMINGTON, Del., Sept. 24, 2026 /PRNewswire/ -- Earendil Labs, an AI-powered biotechnology company advancing next-generation biologics, today announced a research collaboration with Genentech, a member of the Roche Group, to discover and develop multiple therapeutic bispecific antibody programs in oncology.Under the collaboration, Earendil Labs will lead antibody discovery and research through the early clinical development stage for antibody programs directed to certain pre-agreed target combi
Press release cover image

Sep 24, 2026

Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics

Collaboration leverages Atavistik Bio’s proprietary AMPSTM platform to identify and advance novel allosteric small molecules against multiple targets for cardiometabolic diseasesAtavistik Bio to receive $70 million upfront with potential milestone payments up to $1.9B plus tiered royalties CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Atavistik Bio, a clinical-stage biotechnology company advancing a pipeline of hematology therapeutics developed through a novel allosteric discovery platf
A test tube with a colorful liquid in a dimly lit lab setting.

Sep 24, 2026

Orange Boosts Life Science Portfolio With Biolevate Funding

Orange has made a strategic investment in French health-tech startup Biolevate, aiming to enhance its presence in the life sciences sector and foster innovation within the French technology landscape.This funding, facilitated through Orange Ventures, is part of Biolevate's second financing round and positions the company favorably within the French tech ecosystem. Biolevate has been recognized in the 2025 French Tech 2030 program, which promotes technologies deemed crucial for France's technolog
A minimalist illustration of a pill and a molecule on a solid background.

Sep 24, 2026

Lantern Pharma hosts webinar on Open‑Medicine AI multi-agentic drug development platform

Lantern Pharma recently conducted a webinar to showcase its innovative Open-Medicine AI multi-agentic platform aimed at enhancing drug development processes.The live event took place on September 23, 2026, and focused on the capabilities and applications of the Open-Medicine AI platform. This platform is designed to facilitate the integration of multiple agents in drug development, potentially streamlining the process and improving outcomes. For those unable to attend, a recorded version of the
Flat illustration of a stable molecule representing tautomerism in drug discovery.

Sep 23, 2026

Tautomer-Predictor AI Tool Identifies Stable Molecules for Drug Discovery

Researchers at New York University have developed an AI tool, Tautomer-Predictor, that enhances the prediction of stable molecular forms crucial for drug discovery.The innovative model addresses the complexities of tautomerism, where molecules with the same formula can exist in different forms due to the repositioning of hydrogen atoms. This shift, while subtle, can significantly impact how a molecule interacts with protein targets, making accurate tautomer identification vital for effective mol
3D pancreatic cancer model on a lab bench with a tissue sample

Sep 23, 2026

Genialis and Inventia Life Science Collaborate to Link Patient Biology with 3D Pancreatic Cancer Models

Genialis and Inventia Life Sciences have formed a partnership aimed at enhancing the testing of pancreatic cancer treatments by aligning patient biology with advanced 3D cancer models.The collaboration will leverage Genialis’ AI-driven patient insights alongside Inventia’s RASTRUM 3D cell model platform to create human-relevant models of pancreatic ductal adenocarcinoma (PDAC). This initiative is particularly timely, given recent advancements in targeted therapies for pancreatic cancer, which hi
A plant-derived molecule on a lab table with a research notebook in the background.

Sep 23, 2026

Enveda, an AI drugmaker, banks $311M in venture funding

Enveda Biosciences, a Colorado-based company specializing in AI-driven drug discovery, has successfully secured $311 million in Series E funding, marking a significant milestone akin to major biotech IPOs this year.This funding will bolster Enveda's efforts to advance its drug pipeline, which currently includes three candidates undergoing human trials. The company leverages artificial intelligence to analyze molecules derived from plants and microbes, assessing their potential for drug developme
A petri dish with a culture in a dimly lit lab setting, surrounded by research notes.

Sep 23, 2026

37,000 AI Agents Are Running a Virtual Biotech at Stanford

A groundbreaking virtual biotech company has emerged from Stanford Medicine, leveraging 37,000 AI agents to revolutionize drug discovery.This innovative startup, spearheaded by Dr. James Zou and graduate student Harrison Zhang, represents a significant advancement beyond earlier AI projects. Unlike traditional biotech firms, this virtual entity operates without physical infrastructure, relying solely on AI to tackle complex scientific challenges. The system is designed to efficiently analyze vas
A minimalist representation of a drug structure in a flat design.

Sep 23, 2026

Five Pharma Rivals Ran Federated Drug-Discovery AI on 20,000 Secret Structures; It Won

Five major pharmaceutical companies have successfully collaborated to train a cutting-edge AI model on over 20,000 proprietary drug-discovery structures, achieving superior performance compared to publicly available benchmarks. This initiative, led by the AI Structural Biology (AISB) Network, marks a significant advancement in the use of federated learning for drug discovery.The federated model, named AISB-1-Fed, was developed using structural data from AbbVie, Astex Pharmaceuticals, Bristol Mye
A minimalist illustration of a DNA strand and a cell in flat design.

Sep 23, 2026

Anthropic-, Nvidia-Backed Basecamp Research Raise $140M Series C Financing Toward Advancing AI-Designed Drugs

Basecamp Research has successfully completed a $140 million Series C financing round, aimed at advancing its AI-driven drug design capabilities, particularly through its EDEN models for developing innovative cell therapies.This funding will support the training of Basecamp's EDEN (environmentally-derived evolutionary network) models, which are designed to create in vivo cell therapies that can reprogram a patient's cells directly within their body. EDEN utilizes a vast evolutionary dataset to ge
Press release cover image

Sep 23, 2026

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET

Management will also discuss usage patterns, key future milestones, and an overview of the types of collaborations and partnerships under discussionInvestors, collaborators, prospective partners, and interested parties are encouraged to register and see a live demonstration of the platform's key capabilities: Register HereDALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision o
Press release cover image

Sep 22, 2026

XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program

Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities.Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC.MPER vaccine immunogens elicit antibody levels approximately five times those of the study comparator in rhesus macaques; antisera retain antiviral activity at a 1:1,000 dilution.BOSTON and SHENZHEN, China, Sept.